Compare SABS & BPRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SABS | BPRN |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 336.6M | 286.7M |
| IPO Year | 2020 | 2022 |
| Metric | SABS | BPRN |
|---|---|---|
| Price | $3.80 | $42.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 436.6K | 23.8K |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.93% |
| EPS Growth | ★ 78.53 | 74.84 |
| EPS | N/A | ★ 1.95 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.96 |
| Revenue Next Year | N/A | $6.13 |
| P/E Ratio | ★ N/A | $21.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.85 | $29.70 |
| 52 Week High | $5.15 | $43.93 |
| Indicator | SABS | BPRN |
|---|---|---|
| Relative Strength Index (RSI) | 54.08 | 56.67 |
| Support Level | $3.66 | $34.16 |
| Resistance Level | $4.03 | $43.92 |
| Average True Range (ATR) | 0.14 | 1.01 |
| MACD | 0.00 | -0.18 |
| Stochastic Oscillator | 52.50 | 44.52 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Princeton Bancorp Inc is a full-service financial institution providing personal and business banking services, including checking and savings accounts, as well as a range of lending products such as residential, commercial, construction, and consumer loans, including home equity loans and lines of credit. The Bank operates branches and conducts loan origination activities in areas of the New York City metropolitan area. Its loan portfolio is segmented into commercial real estate (including owner-occupied, non-owner-occupied, and multi-family properties), construction loans (mainly for residential developments), commercial and industrial loans (for business purposes), residential real estate loans (secured by one-to-four family properties), and consumer/HELOC loans.